Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study

Lehtinen, Matti; Dillner, Joakim; Knekt, Paul; Luostarinen, Tapio; Aromaa, Arpo; Kirnbauer, Reinhard; Koskela, Pentti; Paavonen, Jorma; Pető, Richárd; Schiller, John T.; Hakama, Matti

doi:10.1136/bmj.312.7030.537

Cited by 136 publications

(85 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most infections are transient, with a median duration of at most 12 months, and pose no risk of cervical neoplasia: only the 10-20% that remain persistent are of concern (Ho et al, 1995;Remmink et al, 1995;Nobbenhuis et al, 1999). Evidence of infection, either by serology in stored blood samples or by viral DNA in fixed archival specimens, is found many years before serious disease is present, and indicates that infection precedes disease (Walboomers et al, 1995;Lehtinen et al, 1996;Dillner et al, 1997). Detection of HPV DNA in the absence of cytological abnormalities can also indicate presence of high-grade cervical intraepithelial neoplasia (CIN) which was missed by cytology .…”

Section: Natural Historymentioning

confidence: 99%

A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions

Cuzick¹,

Sasieni²,

Davies

et al. 2000

Br J Cancer

137

View full text Add to dashboard Cite

A systematic review of the available evidence on the role of HPV testing in cervical screening has been published by the Health Technology Assessment Committee of the UK Department of Health. The review summarized relevant data on testing methods, natural history, and prevalence of the virus in different disease groups. Cost-effectiveness modelling was undertaken. Ten major conclusions were reached and are reported here. The key conclusions were that HPV testing was more sensitive than cytology, but that there were concerns about specificity, especially in young women. The increased sensitivity led to a recommendation that HPV testing be introduced on a pilot basis for women with borderline and mild smears. HPV testing has great potential as a primary screening test, but large trials are needed to properly evaluate this application and to determine if its introduction can reduce invasive cancer rates. There is an urgent need to undertake a large trial of HPV testing in conjunction with other new technologies (liquid-based cytology and computer-assisted cytology reading) to determine the best way to integrate them into ongoing screening programmes. A range of issues including the age to start and stop screening, the appropriate screening interval, the role of self-sampling for HPV testing and the choice of primary test (HPV and/or cytology) require further evaluation. © 2000 Cancer Research Campaign

show abstract

Section: Natural Historymentioning

confidence: 99%

A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions

Cuzick¹,

Sasieni²,

Davies

et al. 2000

Br J Cancer

137

View full text Add to dashboard Cite

show abstract

“…VLP-based ELISAs have been employed extensively to assess the risk association of HPV infection and cervical cancer (19)(20)(21). In South Africa, the exposure to HPV types 16, 18, 31, 33, and 45 has been assessed (21,22).…”

Section: Humoral Immune Responsesmentioning

confidence: 99%

Human Papillomavirus (HPV) Infection in Southern Africa: Prevalence, Immunity, and Vaccine Prospects

et al. 2002

View full text Add to dashboard Cite

SummaryHuman papillomavirus (HPV) associated cancers are more prevalent in developing countries compared to developed countries. The major cancer caused by HPV is cervical cancer. The humoral immune response to HPV can be a marker of past infection but may also reflect persistent infection and cervical disease. IgA antibodies to HPV in oral fluid were also found to be markers of cervical disease. Cell mediated immunity is important in clearing HPV infection and for regression of the associated lesions: this means that women infected with HIV have a high prevalence of co-infection with HPV. Good cervical screening programmes can control HPV associated cervical neoplasia. However, in countries such as South Africa, where these programmes are inadequate, there is a need for an HPV vaccine. The development of HPV vaccines is reviewed. There is a call for an inexpensive vaccine that will be accessible to the women that do not have access to adequate screening programmes and are therefore at the greatest risk of cervical cancer. IUBMB Life, 53: 253-258, 2002

show abstract

“…Serological assays based on HPV capsids, which represent conformational viral epitopes, can detect HPVtype restricted antibodies. These assays have been validated as useful tools for seroepidemiologic studies among various cohorts (Van Doornum et al, 1994Dillner, 1995;Nonnenmacher et al, 1995Nonnenmacher et al, , 1996Wideroff et al, 1995Wideroff et al, , 1996aWikström et al, 1995a, b;Lehtinen et al, 1996).…”

mentioning

confidence: 99%

Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites

et al. 2003

View full text Add to dashboard Cite

A retrospective seroepidemiologic study was performed to examine the association between human papillomaviruses (HPV) 16 infection and carcinomas of the oropharynx, the oesophagus, penis and vagina. Sera were selected from the serum bank from the Antoni van Leeuwenhoek Hospital (Netherlands Cancer Institute) and the Slotervaart Hospital in Amsterdam, the Netherlands. Presence of HPV 16 specific antibody was assessed using HPV 16 L1 capsids. Sera positive for HPV 16 capsid antibody were further tested for antibody against HPV 16 E7 peptides. Prevalence of antibody against HPV 16 L1 capsids among both the negative control group without cancer and the negative control group with gastric cancer was 18%, while seroprevalence among the control group of patients with HPV-associated cervical squamous cell carcinoma was 47% (Po0.001). Among the patients with penile squamous cell carcinoma seroprevalence was 38% (Po0.001), among patients with oropharyngeal carcinoma 33% (P ¼ 0.04) and among patients with oesophageal squamous cell carcinoma 14% (P ¼ 0.7). The serological evidence for association between HPV 16 infection and both oropharyngeal carcinoma and penile carcinoma was established. The conclusion that no association was found between the presence of antibody against HPV 16 L1 capsids and oesophageal squamous cell carcinoma was in accordance with results of other studies carried out in the Netherlands using HPV DNA technology. In the subjects with HPV 16 L1 capsid antibody, no association was found between the antibody against HPV 16 E7 and clinical outcome.

show abstract

Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study

Abstract: This prospective study provides epidemiological evidence that infection with human papillomavirus type 16 confers an excess risk for subsequent development of cervical carcinoma.

Cited by 136 publications

References 11 publications

A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions

A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions

Human Papillomavirus (HPV) Infection in Southern Africa: Prevalence, Immunity, and Vaccine Prospects

Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites

Contact Info

Product

Resources

About